Teachers Advisors LLC raised its stake in shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 225.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 259,325 shares of the biopharmaceutical company’s stock after buying an additional 179,645 shares during the period. Teachers Advisors LLC owned about 0.46% of Portola Pharmaceuticals worth $10,163,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. First Mercantile Trust Co. acquired a new position in shares of Portola Pharmaceuticals during the first quarter valued at $165,000. Ameritas Investment Partners Inc. acquired a new position in shares of Portola Pharmaceuticals during the first quarter valued at $167,000. Fortaleza Asset Management Inc. acquired a new position in shares of Portola Pharmaceuticals during the first quarter valued at $193,000. Credit Agricole S A acquired a new position in shares of Portola Pharmaceuticals during the first quarter valued at $196,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Portola Pharmaceuticals during the first quarter valued at $330,000. Hedge funds and other institutional investors own 86.47% of the company’s stock.
Portola Pharmaceuticals, Inc. (NASDAQ PTLA) traded up 1.45% on Friday, reaching $53.99. The company’s stock had a trading volume of 694,590 shares. The firm has a 50 day moving average price of $60.53 and a 200 day moving average price of $43.46. The stock’s market capitalization is $3.11 billion. Portola Pharmaceuticals, Inc. has a 52 week low of $15.68 and a 52 week high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.12. The company had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.28 million. Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. The firm’s quarterly revenue was down 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.02) earnings per share. On average, equities analysts anticipate that Portola Pharmaceuticals, Inc. will post ($4.86) EPS for the current year.
Several equities research analysts have commented on PTLA shares. Oppenheimer Holdings, Inc. set a $46.00 price objective on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 9th. BidaskClub upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Tuesday, July 18th. Citigroup Inc. set a $51.00 price objective on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 17th. Finally, ValuEngine upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. Portola Pharmaceuticals currently has an average rating of “Buy” and an average price target of $63.77.
In other Portola Pharmaceuticals news, insider John T. Curnutte sold 10,000 shares of the business’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total value of $650,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Tao Fu sold 5,812 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $65.00, for a total transaction of $377,780.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,289,656 shares of company stock worth $91,298,131 in the last 90 days. Company insiders own 4.90% of the company’s stock.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
